

## Corrigendum

# Corrigendum to “Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States”

**Catherine W. Saltus** <sup>1</sup>, **Zdravko P. Vassilev**,<sup>2</sup> **Jihong Zong**,<sup>2</sup> **Brian Calingaert**,<sup>3</sup> **Elizabeth B. Andrews**,<sup>3</sup> **Montse Soriano-Gabarró**,<sup>4</sup> and **James A. Kaye** <sup>1</sup>

<sup>1</sup>RTI Health Solutions, Waltham, Massachusetts, USA

<sup>2</sup>Bayer US, Whippany, New Jersey, USA

<sup>3</sup>RTI Health Solutions, Research Triangle Park, North Carolina, USA

<sup>4</sup>Bayer AG, Berlin, Germany

Correspondence should be addressed to Catherine W. Saltus; [csaltus@rti.org](mailto:csaltus@rti.org)

Received 27 May 2019; Accepted 2 June 2019; Published 4 July 2019

Copyright © 2019 Catherine W. Saltus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States” [1], there was an error in the “2.3. Study Design and Subjects” section, where “(except melanoma)” should be corrected to “(except nonmelanoma skin cancer).”

## References

- [1] C. W. Saltus, Z. P. Vassilev, J. Zong et al., “Incidence of second primary malignancies in patients with castration-resistant prostate cancer: an observational retrospective cohort study in the United States,” *Prostate Cancer*, vol. 2019, Article ID 4387415, 7 pages, 2019.